What a pharma emailer must carry in India
An emailer meant to inform a prescribing decision carries the five items of UCPMP 2024 Clause 3.2. Under Clause 3.3, mailings must not be designed to disguise their real nature. A medical-supervision caution is container-label wording and does not belong on it. Licence conditions in the Drugs and Cosmetics Rules 1945, also apply. They bar any advertisement of Schedule H, H1 or X drugs without previous Central Government sanction.
In short
- Clause 3.2's five items where the emailer informs a prescribing decision, and Clause 3.3, which names mailings explicitly.
- A medical-supervision caution on a doctor-directed emailer is a category error. It is container-label wording, with no basis as a requirement for doctor material. It suggests the audience was never settled.
- Licence conditions in the Drugs and Cosmetics Rules 1945 bar advertising Schedule H, H1 or X drugs without previous Central Government sanction (Rules 74(p), 74A(i), 74B(7), 78(q) and 78A(8)). The text sets no audience limit. How it applies to an emailer sent only to prescribers is a question for your regulatory team.
- The Drugs and Magic Remedies Act 1954 applies to an emailer to doctors too, unless its Section 14(c) saving covers it. That saving needs the manner prescribed under the Act's rules.
- Mandatory information must survive image blocking. If it lives in artwork, it is absent for many readers.
The clause that names this format
Clause 3.3 of UCPMP 2024 says: 'Promotional material such as mailings and journal advertisements must not be designed to disguise their real nature'. An email formatted to look like personal correspondence or like editorial content is what that addresses. Clause 3.9 covers postcards, envelopes and other exposed mailings. They 'must not carry matter which might be regarded as advertising to the lay public, or which could be considered unsuitable for public view'. The clause does not mention email. It is a useful analogy for subject lines and previews.
Do not put a medical-supervision caution on a doctor's email
In the Drugs and Cosmetics Rules 1945, 'Caution: To be taken under medical supervision' is container-label wording. Rule 161(2) requires it on certain Ayurvedic, Siddha and Unani medicines made from a Schedule E(1) substance. It is not a requirement for promotional material to prescribers.
On an emailer to prescribers it adds no safety margin. It signals that the audience of the piece was never settled.
If the piece is for doctors, UCPMP 2024 applies, with Clause 3.2 where it informs a prescribing decision. The Drugs and Magic Remedies Act 1954 still applies to it. The saving written for doctor material is Section 14(c). That covers an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. Whether an email meets the manner prescribed under the Act's rules is a question for your regulatory team.
If the piece is for patients, it is advertising to the public. The Act's Sections 3 and 4 and the Central Consumer Protection Authority's 2022 guidelines then apply.
A Drugs and Cosmetics Rules 1945 licence condition bars advertising Schedule H, H1 or X medicines without previous Central Government sanction. It sits in Rules 74(p), 74A(i), 74B(7), 78(q) and 78A(8). Its text has no audience limit. How it applies to a prescriber-only emailer is a question for your regulatory team.
What the recipient actually sees
Clause 3.2 requires the minimum information to be legible and an integral part of the material. Many email clients block images by default and will not render anything set inside artwork. For those readers, an element that exists only in a banner image is genuinely absent. Mandatory information belongs in live text. Check the piece as rendered with images off.
Frequently asked questions
Does an emailer to doctors need a medical supervision disclaimer?
No. Cautions of that kind are container-label wording under the Drugs and Cosmetics Rules 1945, for example Rule 161(2). They are not a requirement for promotional material to prescribers. An emailer to prescribers falls under UCPMP 2024, with Clause 3.2 where it informs a prescribing decision. The Drugs and Magic Remedies Act 1954 also applies unless its Section 14(c) saving covers the email. That saving is for an advertisement sent confidentially, in the prescribed manner, only to a registered medical practitioner. Including the caution suggests the audience of the piece has not been settled.
Which UCPMP clause covers emailers specifically?
Clause 3.3 names mailings, which is generally read to include email. It requires that they not be designed to disguise their real nature. Clause 3.2 supplies the minimum information where the emailer informs a prescribing decision. Clause 3.9, on postcards, envelopes and other exposed mailings, does not mention email. It is a useful analogy for subject lines and previews. Outside UCPMP 2024, two questions follow. One is whether the Section 14(c) saving in the Drugs and Magic Remedies Act 1954 covers the email. The other is how the Drugs and Cosmetics Rules 1945 Schedule H, H1 and X sanction condition applies. Both are questions for your regulatory team.
Can mandatory information be placed inside the email banner image?
It should not be. Clause 3.2 requires the information to be legible and an integral part of the material. Many email clients block images by default, so anything inside artwork is simply not shown.
Check it before MLR does
Collateral Advisor reviews each page you upload across five dimensions: medical, compliance, visual design, copywriting and best practice.
Free trial, no card needed. MarketingSense is a pre-MLR advisory assistant. Your medical, legal and regulatory team still makes the final call.